
Broad-Based Technical Strength Lifts Emcure Pharmaceuticals Ltd to 52-Week High of Rs 1957.8
2026-07-28 10:20:11With a decisive break above Rs 1957.8 on 28 Jul 2026, Emcure Pharmaceuticals Ltd has reached a fresh 52-week and all-time high, propelled by a confluence of bullish technical indicators and sustained price momentum.
Read full news article
Emcure Pharmaceuticals Ltd is Rated Hold
2026-07-25 10:10:41Emcure Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 05 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 July 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.
Read full news article
Emcure Pharmaceuticals Ltd Technical Momentum Shifts Signal Bullish Outlook
2026-07-15 08:05:30Emcure Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend. This change is underscored by positive signals from key technical indicators such as the MACD, moving averages, and Bollinger Bands, alongside a robust year-to-date return of 32.64%, significantly outperforming the Sensex’s negative 9.58% over the same period.
Read full news article
Emcure Pharmaceuticals Ltd is Rated Hold
2026-07-14 10:10:36Emcure Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 05 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 July 2026, providing investors with the latest insights into its performance and outlook.
Read full news article
Emcure Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Market Signals
2026-07-14 08:06:52Emcure Pharmaceuticals Ltd has experienced a subtle shift in its technical momentum, transitioning from a bullish to a mildly bullish stance as of mid-July 2026. Despite a slight dip in the daily price, the stock’s technical indicators present a nuanced picture, reflecting both resilience and caution within the Pharmaceuticals & Biotechnology sector.
Read full news article
Emcure Pharmaceuticals Ltd Technical Momentum Shifts to Bullish Amid Strong Year-to-Date Gains
2026-07-08 08:06:32Emcure Pharmaceuticals Ltd has recently exhibited a notable shift in its technical momentum, upgrading from a mildly bullish to a bullish stance. This change is underpinned by a confluence of positive signals across key technical indicators including MACD, Bollinger Bands, and moving averages, signalling renewed investor interest and potential upside in the small-cap pharmaceutical stock.
Read full news article
Emcure Pharmaceuticals Ltd Technical Momentum Shifts Amid Mixed Indicator Signals
2026-07-07 08:08:26Emcure Pharmaceuticals Ltd has experienced a subtle shift in its technical momentum, moving from a bullish to a mildly bullish stance as of early July 2026. Despite a slight dip in the daily price, key technical indicators such as MACD, RSI, and moving averages reveal a complex picture of the stock’s near-term trajectory within the Pharmaceuticals & Biotechnology sector.
Read full news article
Emcure Pharmaceuticals Ltd is Rated Hold by MarketsMOJO
2026-07-03 10:11:16Emcure Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 05 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 July 2026, providing investors with an up-to-date view of the company's fundamentals, returns, and market performance.
Read full news articleIntimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Update On Completion Of Acquisition Of Shares Of Gennova Biopharmaceuticals Limited.
22-Jul-2026 | Source : BSEUpdate on completion of acquisition of shares of Gennova Biopharmaceuticals Limited
Announcement under Regulation 30 (LODR)-Change in Management
21-Jul-2026 | Source : BSEIntimation under Regulation 30 of the SEBI (LODR) Regulations 2015 - Completion of 2nd term of Independent Director
Announcement under Regulation 30 (LODR)-Press Release / Media Release
20-Jul-2026 | Source : BSEPress Release titled Emcure to Expand the Use of Poviztra for MASH Indication Following CDSCO Approval.
Corporate Actions
06 Aug 2026
Emcure Pharmaceuticals Ltd has declared 30% dividend, ex-date: 14 Aug 25
No Splits history available
No Bonus history available
No Rights history available







